Literature DB >> 19423411

[Respiratory infections, Down's syndrome and congenital heart disease: the CIVIC 21 study].

C Medrano López1, L García-Guereta Silva, J Lirio Casero, J García Pérez.   

Abstract

INTRODUCTION: We compare hospitalisation rates for acute respiratory tract infection in children younger than 24 months with significant congenital heart disease without Down's syndrome with those with Down's syndrome with or without congenital heart disease.
MATERIAL AND METHODS: This was an epidemiological, multicentre (53 Spanish hospitals), observational and prospective study, from October 2006 to April 2007. A total of 1085 patients were followed-up, of which 806 did not have Down's syndrome and 279 with Down's syndrome: 135 with significant, 38 with non significant and 105 without congenital heart disease.
RESULTS: A total of 147 patients (13.1%; 95% CI, 11.2-15.2%) required hospitalisation due to respiratory infection. Rates in patients without and with Down's syndrome were 11% vs 19.1%. In the Down's group, 26.3% had no significant, a 23% had significant and 11.4% had no congenital heart disease. The main diagnosis was bronchiolitis (59.4%). An infectious agent was found in 36.2% cases. The specific admission rate due to respiratory syncytial virus was 4.4%, with differences in children without vs with Down's syndrome (3.2% vs 7.8%). In the Down's patients we found rates of 15.8%, 9.3% and 3% in the non-significant, significant and no congenital heart disease. Immunoprophylaxis against respiratory syncytial virus rates were 83.4% vs 39.9% in no Down's versus Down's syndrome patients. No differences were found in hospital stay or the severity.
CONCLUSIONS: Hospital admission rates due to respiratory infection, and specifically respiratory syncytial virus, were higher in the Down's patients, particularly in the group with no significant congenital heart disease and low immunoprophylaxis against respiratory syncytial virus.

Entities:  

Mesh:

Year:  2009        PMID: 19423411     DOI: 10.1016/j.anpedi.2008.11.007

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  7 in total

1.  Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.

Authors:  Arne Simon; Susanne Gehrmann; Gudrun Wagenpfeil; Stefan Wagenpfeil
Journal:  Eur J Pediatr       Date:  2018-04-12       Impact factor: 3.183

2.  Increased pro-inflammatory cytokine production in Down Syndrome children upon stimulation with live influenza A virus.

Authors:  Chantal J M Broers; Reinoud J B J Gemke; Michel E Weijerman; Koen F van der Sluijs; A Marceline van Furth
Journal:  J Clin Immunol       Date:  2011-12-15       Impact factor: 8.317

3.  Pandemic (H1N1) 2009 virus and Down syndrome patients.

Authors:  Rogelio Pérez-Padilla; Rosario Fernández; Cecilia García-Sancho; Francisco Franco-Marina; Octavio Aburto; Hugo López-Gatell; Ietza Bojórquez
Journal:  Emerg Infect Dis       Date:  2010-08       Impact factor: 6.883

4.  Epidemiological and clinical data of hospitalizations associated with respiratory syncytial virus infection in children under 5 years of age in Spain: FIVE multicenter study.

Authors:  David Moreno-Perez; Cristina Calvo
Journal:  Influenza Other Respir Viruses       Date:  2014-01-02       Impact factor: 4.380

5.  The impact of congenital heart diseases on the quality of life of patients and their families in Saudi Arabia. Biological, psychological, and social dimensions.

Authors:  Ahmad S Azhar; Zahra H AlShammasi; Rawan E Higgi
Journal:  Saudi Med J       Date:  2016-04       Impact factor: 1.484

Review 6.  Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases.

Authors:  Paolo Manzoni; Josep Figueras-Aloy; Eric A F Simões; Paul A Checchia; Brigitte Fauroux; Louis Bont; Bosco Paes; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-06-26

7.  Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.

Authors:  Manuel Sánchez-Luna; Constancio Medrano; Julián Lirio
Journal:  Influenza Other Respir Viruses       Date:  2016-12-30       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.